help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by CHARPIN, J.-M.
Right arrow Articles by ISRAËL-BIET, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by CHARPIN, J.-M.
Right arrow Articles by ISRAËL-BIET, D.

Am. J. Respir. Crit. Care Med., Volume 161, Number 6, June 2000, 1991-1998

Insulinlike Growth Factor-1 in Lung Transplants with Obliterative Bronchiolitis

JEAN-MARIE CHARPIN, MARC STERN, DOMINIQUE GRENET, and DOMINIQUE ISRAËL-BIET

Laboratoire d'Immunologie Pulmonaire and Service de Pneumologie, Hôpital Laënnec, Paris; Service de Pneumologie, Hôpital Foch, Suresnes, France

Bronchiolitis obliterans syndrome (BOS) is the major complication limiting survival of lung transplant recipients (Tx patients). The mechanisms underlying this fibrotic process are not known. We assessed IGF-1 and IGFBP-3 expression, critical mediators in different models of pulmonary fibrosis, in nine Tx patients. Three of them developed a BOS at 8, 14, and 17 mo postgraft, respectively. Two of the remaining six displayed a recurrent cytomegalovirus (CMV) infection, and four are in stable condition. IGF-1 mRNA expression was quantitated by RT-PCR in cells from four to six BAL per patient performed during the first 6 mo postgraft. Contrasting with a constantly low expression of IGF-1 mRNA in BAL cells from the six patients without BOS, the three patients with BOS presented marked peaks of IGF-1 on two to five occasions during the study period. These peaks, 3- to 13-fold increased compared with values from the former patients, preceded the diagnosis of BOS by 7, 13, and 17 mo, respectively. On the other hand, IGFBP-3 was highly and exclusively expressed in the three patients with BOS, the mRNA as well as the gene product as demonstrated by Western blotting. Our data strongly argue for a role of IGF-1 and IGFBP-3 in the fibrotic process underlying BOS, and for their possible value as an early marker of this complication.




This article has been cited by other articles:


Home page
 Proc Am Thorac SocHome page
J. A. Belperio, S. S. Weigt, M. C. Fishbein, and J. P. Lynch III
Chronic Lung Allograft Rejection: Mechanisms and Therapy
Proceedings of the ATS, January 15, 2009; 6(1): 108 - 121.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
D. M. Murphy, I. A. Forrest, P. A. Corris, G. E. Johnson, T. Small, D. Jones, A. J. Fisher, J. J. Egan, T. E. Cawston, C. Ward, et al.
Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients
Am J Physiol Lung Cell Mol Physiol, March 1, 2008; 294(3): L592 - L599.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
J. D. Lande, J. Patil, N. Li, T. R. Berryman, R. A. King, and M. I. Hertz
Novel Insights into Lung Transplant Rejection by Microarray Analysis
Proceedings of the ATS, January 1, 2007; 4(1): 44 - 51.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
B. S. Lu, A. D. Yu, X. Zhu, E. R. Garrity Jr, W. T. Vigneswaran, and S. M. Bhorade
Sequential gene expression profiling in lung transplant recipients with chronic rejection.
Chest, September 1, 2006; 130(3): 847 - 854.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
L. P. Nicod
Mechanisms of airway obliteration after lung transplantation.
Proceedings of the ATS, July 1, 2006; 3(5): 444 - 449.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Boehler and M. Estenne
Post-transplant bronchiolitis obliterans
Eur. Respir. J., December 1, 2003; 22(6): 1007 - 1018.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
O. Ibrahim-Granet, B. Philippe, H. Boleti, E. Boisvieux-Ulrich, D. Grenet, M. Stern, and J. P. Latge
Phagocytosis and Intracellular Fate of Aspergillus fumigatus Conidia in Alveolar Macrophages
Infect. Immun., February 1, 2003; 71(2): 891 - 903.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Estenne and M. I. Hertz
Bronchiolitis Obliterans after Human Lung Transplantation
Am. J. Respir. Crit. Care Med., August 15, 2002; 166(4): 440 - 444.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. M. Aris, S. Walsh, W. Chalermskulrat, V. Hathwar, and I. P. Neuringer
Growth Factor Upregulation during Obliterative Bronchiolitis in the Mouse Model
Am. J. Respir. Crit. Care Med., August 1, 2002; 166(3): 417 - 422.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1789 - 1804.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society 		  ATS Clinical Skills Tests